BMC Research Notes 2014, 7:367 (doi:10.1186/1756-0500-7-367)
Authors
David Thorne1, Joanne Kilford2, Rebecca Payne2, Linsey Haswell1, Annette Dalrymple1, Clive Meredith1 and Deborah Dillon1
1 British American Tobacco, Group R&D, Southampton, Hampshire SO15 8TL, UK
2 Covance Laboratories Ltd, Otley Road, Harrogate, North Yorkshire HG3 1PY, UK
Mainstream cigarette smoke and the gase vapour phase, generated with the VC 10® smoke exposure system, indicates significant differently in-vitro cytotoxicity profiles. The used method on the air-liquid interface takes into account the synergies of both the particulate and vapour phase of tobacco smoke in the NRU assay.
